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Corona virus disease 2019 (COVID-19) is a global public health crisis. The high
infectivity of the disease even from non-symptomatic infected patients, together with
the lack of a definitive cure or preventive measures are all responsible for disease
outbreak. The severity of COVID-19 seems to be mostly dependent on the patients’
own immune response. The over-activation of the immune system in an attempt to
kill the virus, can cause a “cytokine storm” which in turn can induce acute respiratory
distress syndrome (ARDS), as well as multi-organ damage, and ultimately may lead
to death. Thus, harnessing the immunomodulatory properties of mesenchymal stem
cells (MSCs) to ameliorate that cytokine-storm can indeed provide a golden key for the
treatment of COVID-19 patients, especially severe cases. In fact, MSCs transplantation
can improve the overall outcome of COVID-19 patients via multiple mechanisms; first
through their immunomodulatory effects which will help to regulate the infected patient
inflammatory response, second via promoting tissue-repair and regeneration, and third
through their antifibrotic effects. All these mechanisms will interplay and intervene
together to enhance lung-repair and protect various organs from any damage resulting
from exaggerated immune-response. A therapeutic modality which provides all these
mechanisms undoubtedly hold a strong potential to help COVID-19 patients even those
with the worst condition to hopefully survive and recover.
Keywords: COVID-19, cytokine storm, extracellular vesicles, exosomes, immunomodulation, mesenchymal stem
cells, SARS-CoV-2, corona virus

INTRODUCTION
Corona virus disease-2019 (COVID-19) is a devastating growing pandemic. As of 6th September
2020, the World health Organization (WHO) has reported 26,763,217 confirmed cases and
876,616 confirmed deaths resulting from COVID-19 globally (World Health Organization
[WHO], 2020a). The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is the
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or lung disease, diabetes, or conditions that might affect their
immune system are at most risk for developing severe COVID-19
(World Health Organization [WHO], 2020b).

inducing initiating factor which causes COVID-19 (Gorbalenya
et al., 2020). The viral infection occurs mainly due to aerosol
particles resulting from talking and breathing of an infected
person, which pose an infection-threat if they are transferred to
a nearby person (Meselson, 2020). Moreover, if these particles
settle on surfaces, they represent a contact hazard since the virus
remains infective/viable for several hours (at least) depending
on the nature of the surface (van Doremalen et al., 2020).
Unfortunately, SARS-CoV-2 is characterized by being highly
infectious, and in the same time capable of evading the human
immune-response; both features may at least partially explain
the COVID-19 outbreak (Shang et al., 2020a). It is important
to point here that SARS-CoV-2 enters the human cells via
angiotensin-converting enzyme 2 (ACE2) receptor; a process
in which human proteases act as entry-activators (Shang et al.,
2020a,b). Moreover, Shin and coworkers recently highlighted
how SARS-CoV2 utilizes a papain-like protease to cleave ISG15
(an ubiquitin-like protein) from interferon responsive factor 3
(IRF3). This attenuates the type I interferon responses, and helps
the virus to evade immune response (Shin et al., 2020).

Immunopathology of COVID-19
Severe acute respiratory syndrome corona virus-2 or COVID-19
is a member of coronoviridae virus family. It is an enveloped
single RNA strand virus with a spherical virion and spiked
glycoprotein, hence the popular name of corona virus of this
family (Allegra et al., 2020). After entering the lungs through
respiration, SARS-CoV-2 stimulates the activity of immune cells
and increase cytokine production. As any other RNA virus,
SARS-CoV-2 can be identified through toll like receptor (TLR)
which stimulates IFN-γ production and activates CD8 + T cells,
natural killer cells and macrophages (Nelemans and Kikkert,
2019). The infected cells then present the viral antigen as
portions of surface antigen-MHC-I complexes which activates
cytotoxic T-lymphocytes (Baruah and Bose, 2020). SARS-CoV
and MERS-CoV infections are characterized by fast and robust
initial virus replication with late IFN generation, resulting in
disproportionate inflammatory host responses provoking grave
lung alterations (Kindler and Thiel, 2016). In the fight between
the virus and the human body, the immunity of the subjects
reduces, and the virus virulence augments. This causes edema
and congestion of the lung, thickening of the interstitial tissue,
and augmented exudation in the alveolar space able to cause
respiratory failure (Han et al., 2020).
As for SARS-CoV-2 interactions with the immune cells,
several studies showed that T-cells, B-cells and NK cells were
significantly reduced in patients. Besides, T-cytotoxic and even
T-helper cells were all below normal range (Liu et al., 2020; Qin
et al., 2020). In addition, cytokines play important role in the
immunopathology of the viral infection. Many cytokines were
found to be elevated in SARS-CoV-2 infected subjects including
IL-1β, IFN-γ, monocyte chemoattractant protein-1 (MCP-1), IL17, IL-2R, and IL-6 (Huang et al., 2020; Zhang W. et al., 2020).
Not only are these cytokines elevated, but also they are correlated
with the disease severity (Chen L. et al., 2020). Of special interest
of these cytokines, several reports have analyzed IL-6 plasma
concentration. Most studies tend to consider IL-6 elevated levels
as a negative factor in SARS-CoV-2 pneumonia. IL-6 can inhibit
CD8 + cytotoxic T-cells by reducing IFN-γ and it can block
antiviral response during the cytokine storm (Velazquez-Salinas
et al., 2019). That’s the reason why IL-6-R antagonist tocilizumab
has found its way to many of the current protocols used to control
COVID-19 mediated pneumonia. However, IL-6 also plays an
essential role in lung repair responses after viral injury, suggesting
that the timing of administration of anti-IL6R could interfere
with correct tissue remodeling (Okabayashi et al., 2006).
Actually, usually in the beginning of the SARS-CoV-2
infection, the patients are presented with mild symptoms,
however, the clinical condition is worsened unexpectedly in later
stage of the disease due to what is called “cytokine storm”
causing ARDS and multiple organ failure (Teijaro et al., 2014).
Hence, controlling this cytokine storm is essential for treating
the COVID-19 ARDS. Beside the previously described cytokines,

COVID-19 Clinical Presentation and
Complications
The clinical presentation of COVID-19 ranges from
asymptomatic presentation to severe respiratory-tract infection
in the form of pneumonia, which can be fatal (Deshmukh et al.,
2020; Tay et al., 2020). In fact, not all patients infected with
SARS-CoV-2 develop severe respiratory illness (Shi et al., 2020).
Most of the COVID-19 patients will experience relatively mild
symptoms such as dry cough, fatigue, fever, and myalgia (Li
et al., 2020). However, severe COVID-19 cases can progress to
acute respiratory distress syndrome (ARDS) with significant
hypoxia, as well as multi-organ involvement such as renal-failure,
heart-failure, liver-damage, and shock which precipitates death
(Zaim et al., 2020). High incidence of venous thromboembolic
complications and abnormal coagulation variables have also
been noted during the investigations of COVID-19 autopsies
(Deshpande, 2020).
It’s important to point here that both mild and severe
forms of COVID-19 have been reported to be associated with
changes in circulatory cytokine levels such as IL-6, IL-1β, and
others (Wang J. et al., 2020). Moreover, severe complications
of COVID-19 are associated with the hyper-production of
cytokines, known as “cytokine storm” (Shi et al., 2020; Wang
J. et al., 2020). Thus, the immune-response is undoubtedly one
of the key determinants not only of the susceptibility but also
of the disease-severity. On one hand, weak immune system can
increase the risk of SARS-CoV-2 infection. While on the other
hand, hyper-inflammatory response to the viral-infection can
be responsible for the disease severe complications (Shi et al.,
2020; Zaim et al., 2020). Furthermore, accumulating evidence
suggests that cytokine-storm is the main predictor of mortality,
and that identification and treatment of hyper-inflammation
is recommended to reduce the rising mortality (Mehta et al.,
2020). It’s also important to highlight here that elderly people
(over 60 years), and those with health conditions such as heart
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studies showed that cytokine storm is related to T-helper17 (Th17) responses. IL-1β and TNF-α both increase Th17
responses and vascular permeability and leakage. Th17 cells
themselves generate IL-17, IL-21, IL-22, and GM-CSF. IL-17
exerts pro-inflammatory actions by promoting the production
of inflammatory cytokines such as IL-1β, IL-6, G-CSF, TNF-α,
and chemokines such as IL-8, IP10, KC, MIP2A, MIP3A capable
of recruiting more immune cells, and matrix metalloproteinases
that contribute to tissue injury and remodeling. IL-17 and TNFα are able to increase the production of mucins, serum amyloid
A, fibrinogen, and anti-apoptotic proteins (Zenewicz, 2018). This
huge production of cytokines from uninhibited immune system
is the key element that determines the severity of the symptoms
and the mortality rate in SARS-CoV2 infection (Henderson
et al., 2020). Due to the action of pro-inflammatory proteins,
vascular permeability increases and a great amount of fluid
enters the alveoli, causing dyspnea and respiratory failure (LeivaJuarez et al., 2018). The therapeutic approaches used in the
treatment of the various cytokine release syndromes (CRSs)
could be useful for the cytokine storm of SARS-CoV-2 infection
(Allegra et al., 2020).
It is not clear why some patients may develop cytokine storm
while others not. However, several studies have addressed key
players of this cytokine storm. Several of these studies reported
elevated levels of IL-6 as an essential player in the development
of such cytokine storm (Gao Y. et al., 2020; Ruan et al., 2020).
Another study analyzing data from 21 patients in China reported
increased levels of IL-10, IL-6, and TNF-α in severe cases
(Chen G. et al., 2020). This indicates that assessment of IL-6
should be considered as a determinant or predictive marker for
development of such cytokine storm which may help to prevent
adverse consequences in severely ill patients.
It’s worth noting here that another immune response
molecular pattern that haven’t been extensively explored in cases
of COVID-19 is the damage associated molecular pattern, DAMP
for short and their counteracting molecules or suppressants,
SAMP for short (Land, 2020). These are endogenous molecules
such as high mobility group box 1 (HMGB1), S100 proteins,
nuclear and mitochondrial DNA (nDNA and mtDNA), and
extracellular histones that can be released or secreted by death
stimuli or cytokines and can further stimulate the immune
response (Tang et al., 2012). Among these, HMGB1 is a potential
target of SARS (Chen et al., 2004). It can be easily assumed
that HMGB1 can have same role in COVID-19 especially that
some drugs that target HMGB1 such as chloroquine, can prevent
septic shock through inhibition of HMGB1 (Yang et al., 2013),
inhibit SARS-CoV-2 replication/infection in vitro (Wang M.
et al., 2020) and meanwhile proved some clinical efficacy in
some trials (Gao J. et al., 2020). Another interesting target is
Transmembrane protein 173, TMEM173, which is one of the
intracellular immune regulator to pattern recognition receptors
(PRR) activation during infection and tissue injury (Tang
et al., 2020). However, these DAMPs and SAMPs worth further
investigation, not only for a search of specific molecular pattern
that would help to better diagnose COVID-19, but also for
mining of additional therapeutic targets that can either control
the hyper-inflammatory response or halt the viral replication.
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Immunomodulatory Therapeutic
Strategies for COVID-19
The hyper-inflammation state or “cytokine release storm”
induced by COVID-19 is the basis of how immune-modulatory
and/or immunosuppressive-drugs found their way to the
different treatment-protocols used for severe cases of COVID19. One of these drugs is tocilizumab, an IgG1 subclass antibody
that inhibits IL-6 receptor (World Health Organization [WHO],
2020b). It is approved for treating inflammatory/autoimmune
diseases such as rheumatoid arthritis (Shin et al., 2020). Despite
the fact that immunosuppressive-drugs are generally not
recommended during viral infections (Russell et al., 2020),
tocilizumab has been tested in COVID-19 patients with elevated
IL-6 levels, and exhibited several beneficial effects (Witkowski
et al., 2016; Moll et al., 2019). Currently, registered multicenter
randomized controlled phase-II clinical trials to further assess
its efficacy and safety for COVID-19 are recruiting patients
(NCT04335071 and ChiCTR2000029765) (ClinicalTrials.gov,
2020; Chinese Clinical Trial Registry, 2020). Recently,
tocilizumab was added to remdesivir for hospitalized-patients
with severe COVID-19-induced pneumonia in REMDACTA
study (NCT04409262) (ClinicalTrials.gov, 2020). By the way, the
only evidence-based COVID-19 available treatment is remdesivir
which is a viral RNA-polymerase inhibitor that shortens time to
hospital discharge (Beigel et al., 2020).
Another popular immunosuppressive-drug whose association
with decreased-mortality was considered a “breakthrough” in
our battle with COVID-19 is dexamethasone. Severe COVID19 patients given 6 mg dexamethasone once daily had 8–26%
lower mortality compared to patients with standard care in
RECOVERY study (Group, 2020; Mahase, 2020). Although this
study raised enormous enthusiasm about having an affordabledrug for COVID-19, however, some concerns were also raised.
Generally, corticosteroids have wide effects on both innate and
adaptive-immunity and the United States Center for Disease
Control and Prevention (CDC) recommends against the use of
corticosteroids in patients with corona-virus infection (Arabi
et al., 2018). In addition, the RECOVERY results recommend
the use of dexamethasone in patients with severe respiratorydistress syndrome and not out-patients (Group, 2020). However,
there exists a gap of evidence in the study remaining to be
fulfilled including the long term effect of dexamethasone, its
effect in old-aged patients, the timing, the dose and even the
type of corticosteroid needs further investigations (Johnson and
Vinetz, 2020). In the middle of this feverish race to develop new
treatment-protocols, repositioning old drugs to treat COVID-19
or even achieve a radical solution for this pandemic by developing
a COVID-19 vaccine, mesenchymal stem cells (MSCs) appear at
the end of the tunnel as a potential treatment which deserve to be
considered carefully not only for this COVID-19 crisis but also
for other viral infections that may occur in the future.

Mesenchymal Stem Cells Therapy for
Pulmonary Diseases
The main fascination about MSCs lies in their reported
potential to exert protective and reparative effects on an
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provide a novel effective therapeutic modality for inflammatory
lung-disease (Yen et al., 2020).
Interestingly, MSCs have also been suggested to shape
their immunomodulatory actions according to the microenvironment they encounter (Rolandsson Enes and Weiss,
2020). Such notion, at least partially, explains their therapeutic
efficacy in various inflammatory-disease conditions despite their
totally different context and background. Furthermore, these
adaptive immunomodulatory properties of MSCs could provide
a particular therapeutic benefit for ARDS being an acute multifaceted heterogeneous disorder with several differences in host
environment (Rolandsson Enes and Weiss, 2020). Not only that,
but also provides an advantage for MSCs compared to inhibitors
for individual pro-inflammatory cytokines, or recombinant antiinflammatory ones. Nevertheless, it’s noteworthy that despite
the encouraging results from pre-clinical studies, and also the
reported safety of MSCs in several phase-I clinical studies,
the clinical evidence for efficacy in patients is still evolving
(Rolandsson Enes and Weiss, 2020).

amazingly wide-spectrum of tissue injury (Pittenger et al.,
2019). This is further reinforced by their ease of isolation
and large ex vivo expansion capacity, as well as demonstrated
multipotency and immunomodulatory activities (Gao et al.,
2016). MSCs can be isolated from various sources such as; bonemarrow, adipose-tissue, as well as umbilical-cord Wharton’s
jelly (WJ-MSCs) (Pittenger et al., 2019). However, several
reports showed that MSCs derived from different tissues have
different transcriptomic-profile, as well as varying in-context
biological/therapeutic properties (Fong et al., 2011; El Omar et al.,
2014; Barrett et al., 2018).
One of the universal properties of MSCs regardless their
source or type is their immune-modulatory effects. These
immune-modulatory effects are mediated through both paracrine
and direct cell-to-cell contact (Ma et al., 2014). MSCs can
actually affect all types of immune cells including T-lymphocytes,
natural killer cells and dendritic cells (Weiss and Dahlke,
2019). Additionally, MSCs secrete a plethora of cytokines which
represent the corner-stone for their immune-modulatory actions
(Weiss et al., 2008). These immunomodulatory-properties
enabled MSCs to find their way toward inflammatory diseases
such as graft-versus-host-disease (GVHD) (Zhao et al., 2019).
Likewise, these properties are the basis why MSCs can find its way
in the treatment of COVID-19, specifically its ARDS.
Actually this is not the first time we turn our heads toward
MSCs as a potential therapy for pulmonary lung-diseases. Over
the past years, several reports highlighted the therapeutic efficacy
of MSCs for experimental models of lung-diseases such as ARDS
(Matthay, 2015), and chronic obstructive pulmonary disease
(COPD) (Cruz and Rocco, 2020). We think two major properties
of MSCs nominate them as a potential therapeutic modality
for lung-diseases such as COVID-19-induced pneumonia. First,
MSCs have shown high degree of tropism/homing to lungs, after
their intravenous application (the most common route of cell
therapy application); infused MSCs were detected in the lungs
of patients within 30 min (Savukinas et al., 2016; Armitage
et al., 2018). In fact, high percentage of cells lodge in the lungs
(Yen et al., 2020), a phenomenon that is further increased with
inflammation (Ortiz et al., 2003). These cells are cleared within
24–48 h with delayed clearance during inflammatory-conditions
(Armitage et al., 2018).
Second, and more importantly, while lodging in the
lung, these cells are able to secrete a wide variety of soluble
cytokines, angiogenic factors and extracellular-vesicles (EVs)
that can efficiently ameliorate this inflammatory-condition
(Khoury et al., 2020). In fact, preclinical studies proved
that MSCs not only have anti-inflammatory effects but
also antifibrotic, angiogenic and microbicidal effects in
chronic lung-diseases (Cruz and Rocco, 2020). Moreover,
MSCs-derived micro-vesicles were reported to repair the
endothelial cells of cultured injured human lungs via delivery
of angiopoietin-1 to those cells; which helped to restore
protein permeability (Hu et al., 2018). As for their antimicrobial activity, this is mediated through secretion of
antimicrobial peptides/proteins such as hepcidin, β-defensin2, cathelicidin-LL-37, and lipocalin-2 (Alcayaga-Miranda
et al., 2017). Accordingly, MSCs are strongly suggested to
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Mesenchymal Stem Cells Therapy for
COVID-19 ARDS
Given all these beneficial immune-modulatory actions of MSCs
in lung-disease, and the COVID-19-induced “cytokine storm,”
MSCs can be easily considered a potential therapy for COVID19 ARDS. Actually, MSCs can act through several axes in
combating COVID-19 induced lung injury. First, MSCs can
prevent the huge release of the cytokines which activate
the immune system of the patients, thereby alleviating the
“cytokine storm” associated with COVID-19 infection and
considered the main cause of ARDS in these patients (Golchin
et al., 2020; Mehta et al., 2020). Interestingly, the pattern
of anti-inflammatory mediators released are specific to the
inflammatory lung environment. For example, RNA viruses
like COVID-19 activates TLR3 leading to MSCs activation
(Waterman et al., 2010). In addition, MSCs were found to
suppress the inflammation induced lung injury through their
immune modulatory properties. MSCs produce prostaglandinE2 and IL-10 which suppress macrophages, reduce production
of inflammatory cytokines and reduce neutrophils recruitment to
the lung (Devaney et al., 2015; Taghavi-Farahabadi et al., 2020).
Second, MSCs have also tissue repair potential and can repair
the lung tissues especially type II alveolar cells. MSCs have the
ability to secrete angiopoietin-1 (Ang-1) and keratinocyte growth
factor (KGF) which contribute to the restoration of alveolar–
capillary barriers disrupted as part of ARDS pathogenesis (Lee
et al., 2013; Matthay, 2015). In addition, MSCs can restore the
epithelial protein permeability by secretion of angiopoietin-1
(Harrell et al., 2019). Hereby, MSCs not only can prevent hyperinflammation state but also can induce endogenous lung-repair
(Golchin et al., 2020).
These mechanisms were completely demonstrated in 2 very
recent phase-1 clinical trials. The first one was on seven patients
with single dose of MSCs lacking ACE-2 (Leng et al., 2020).
The symptoms of all the patients and pulmonary functions
improved 2 days after transplantation and no adverse effects were
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MSCs to assess the suitability of its use with COVID-19 before
clinical application. To the best of our knowledge, there are
no data regarding the possibility of the infection of MSCs with
COVID-19, which indeed requires further investigations.

seen 14 days. Peripheral lymphocytes were increased, C-reactive
protein was decreased, and natural killer cells disappeared
3–6 days post-transplantation. In addition, TNF-α level was
declined while IL-10, an inhibitory cytokine, was increased.
Interestingly, the chest computed tomography (CT) scan on
the ninth day after MSC transplantation revealed that groundglass opacity and inflammation of pneumonia were significantly
decreased in MSCs group.
Another more recent clinical report by Meng et al., 2020,
who explored transplantation of 3 doses of UC-MSCs at 3 days
interval in nine patients as compared to another nine placebo
receiving patients, can prove both efficacy and safety of UCMSCs treatment in critical-ill COVID-19 patients. Interestingly,
MSCs receiving patients showed lower IL-6 levels than placebo
receiving patients and the authors pointed out that MSCs showed
the most benefit with patients exhibiting hyper inflammation
status (Meng et al., 2020). These 2 clinical trials although
proved efficacy and safety of the MSCs treatment for COVID19, however, phase 2/3 clinical trials, multi-centered and on a
greater number of patients are mandatory to confirm the above
promising results.
It’s important to point here that a typical immune-response
to viral infection is interferon-gamma (IFN-γ), which represents
an important cross-talk between COVID-19 and MSCs. An
unpublished data from Italy showed that COVID-19 patients
may have elevated levels of IFN-γ, which may affect MSCs
therapy (Massimo Dominici, University Hospital of Modena
and Reggio Emilia, Modena, Italy) (Khoury et al., 2020). IFN-γ
acts as an activator of MSCs to exert their immunomodulatory
actions. These activated-MSCs may suppress T-lymphocyte
activation/proliferation for viral infection control (Malcherek
et al., 2014). Also, UC-MSCs inhibit the cytotoxicity of specific
T-cells against H1N1 influenza in vitro leading to prolonged
infections (Liu et al., 2015). These issues highlight the importance
of maintaining delicate balance to fully use the immunesuppressive properties of MSCs to prevent the cytokine-storm,
meanwhile, maintain the whole body defense mechanisms
toward the viral load.
Another important issue in the cross-talk between MSCs and
COVID-19 is the expression of angiotensin converting enzyme2 (ACE-2) receptor. This is the main host cell receptor for the
SARS-CoV-2 entry (Perrotta et al., 2020). Also, this explains
the entry of the virus into the respiratory epithelial cells as this
receptor is highly expressed in type II lung alveolar cells (Xu
et al., 2020; Zou et al., 2020). Nevertheless, it is important to
point here that regarding definite reports highlighting which cells
could be infected with SARS-CoV-2, and which cells could not
be infected with the virus, such data is still emerging, and far
from complete elucidation. Another study has shown that the
cellular protease TMPRSS2 is also required to allow the entry of
coronavirus into host cells (Hoffmann et al., 2020). It is important
for MSCs to be free from SARS-CoV-2 viral infection to exert
its actions properly. This was demonstrated in a recent study in
China which showed that ACE− MSCs, which are free of viral
infection, can ameliorate COVID-19 pneumonia (Leng et al.,
2020). This raises the suggestion that the expression of ACE2receptor and TMPRSS2 should be evaluated in different types of

Frontiers in Cell and Developmental Biology | www.frontiersin.org

Mesenchymal Stem Cells Paracrine
Signaling and Extracellular-Vesicles
Apart from the cross-talk between MSCs, COVID-19 and
immune-cells, generally, a growing body of research has revealed
that therapeutic effects of MSCs occur largely via paracrine
signaling which can bypass this direct contact among MSCs and
the virus (Zhang et al., 2015; Taghdiri et al., 2018). In many cases,
exosomes/extracellular-vesicles (EVs) secreted by MSCs have
been reported to mediate such beneficial effects (Newton et al.,
2017). Exosomes/EVs act as shuttles transferring specific cargos
of mRNA, non-coding RNAs, as well as proteins; resembling a
message in a bottle. Accordingly, they can reprogram recipient
cells due to their active molecular cargo, thus regarded as
“signalosomes” for controlling fundamental cellular functions (El
Andaloussi et al., 2013; Bjorge et al., 2018).
It’s noteworthy that exosomes sparked great interest as a
possible cell-free alternative to current stem cell therapies.
Like their parent cells, exosomes have been reported to
stimulate cellular regeneration, functional recovery in various
pathological conditions (Derkus et al., 2017). Moreover, recently
MSC-derived EVs have been reported to suppress fibrosis
by preventing differentiation of fibroblasts into myofibroblasts
(Basalova et al., 2020).
When considering the therapeutic efficacy of MSCs-derived
EVs compared to their parent cells for lung-diseases, that issue
is a bit controversial. On one hand, an interesting pre-clinical
study reported that MSCs are generally more effective than
their EVs at reducing lung injury in ARDS (Silva et al., 2019).
On the other hand, several pre-clinical reports highlighted the
therapeutic efficacy of MSCs-derived secretome/EVs for various
lung-diseases, through reduction of pro-inflammatory cytokines’
levels, and restoration of lung architecture. Collectively, these
findings encouraged researchers nowadays to consider how to
utilize MSCs-secretome to develop a high quality, safe and
effective medicinal product (Bari et al., 2019).

Clinical Trials for MSCs and
MSCs-Derived EVs for COVID-19
Currently, about 66 clinical trials are registered in the public
clinical trial database to investigate the therapeutic safety/efficacy
of MSCs for COVID-19 (Accessed on 6th September, 2020)
(ClinicalTrials.gov, 2020). Most of these trials are applying
allogenic intra-venous route of cell-therapy, with MSCs derived
mostly from umbilical-cord, adipose-tissue or bone-marrow.
Currently, two registered studies are investigating therapeutic
efficacy of EVs derived from MSCs via the intra-nasal route
(ClinicalTrials.gov, 2020). Being a global health crisis, these
trials are originating from several countries including China, the
United States, Canada, Jordan, as well as, several countries in
Europe such as Spain, and Germany. These various clinical trials
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FIGURE 1 | A schematic presentation for the different types of mesenchymal stem cells and their various therapeutic strategies implicated in COVID-19 treatment.
MSCs and their derived EVs can efficiently intervene via several mechanisms to improve the overall outcome of COVID-19 especially in critically-ill patients with
severe symptoms. These mechanisms include their immunomodulatory activities, tissue regenerative effects, anti-microbial effects, as well as their antifibrotic and
angiogenic effects. AD, Adipose tissue; BM, Bone marrow; COVID-19, Corona Virus Disease-2019; EVs, Extra-Cellular vesicles; MSCs, Mesenchymal Stem Cells;
and WJ, Wharton’s Jelly. Created by Biorender.com.

FIGURE 2 | A summary for the critical issues that should be carefully considered when selecting a certain type of mesenchymal stem cells for COVID-19 treatment.
AD, Adipose tissue; ACE2, Angiotensin converting enzyme; BM, Bone marrow; COVID-19, Corona Virus Disease-2019; MSCs, Mesenchymal Stem Cells;
TF/CD142, Tissue factor; SARS-CoV-2, Severe acute respiratory syndrome corona virus-2; TMPRSS2, Transmembrane protease serine 2 and WJ, Wharton’s Jelly.
Created by Biorender.com.

investigating MSCs for COVID-19 are reviewed elsewhere in
detail (Golchin et al., 2020; Rajarshi et al., 2020; Yen et al., 2020).
Generally, the allogenic transplantation of MSCs is preferred
rather than the autologous one in case of COVID-19. This
is primarily due to the rapid deterioration of COVID-19,
especially in severe cases, in such a way that there will
probably be no time for autologous harvesting followed by 2–
3 weeks of MSCs expansion in culture (Yen et al., 2020). It’s
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noteworthy here that in support of allogenic MSCs intervention,
generally MSCs in clinical studies for various diseases do not
require human-leukocyte-antigens (HLA)-matching procedures.
This also adds to their credit and therapeutic potential for
the rapidly deteriorating COVID-19 context. Besides, some
concerns regarding whether or not autologous MSCs from
SARS-CoV-2 infected patients are infected with the virus, and
whether the overall status of the infected-patient might affect
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till the end of follow-up period. Moreover, the authors reported
that MSCs expressed neither ACE2, nor TMPRSS2, which could
provide them with natural immunity to SARS-CoV-2 (Leng
et al., 2020). Despite the interesting findings, it’s important
to remember that the study was indeed limited by the small
patients’ cohort.

these autologous-MSCs. Additionally, it’s noteworthy that MSCs
count/function have been reported to decline with age (Pittenger
et al., 2019), since the elderly are among the most vulnerable
to suffer severe COVID-19, thus autologous option is absolutely
questionable in those patients.
Again, this preference for allogenic transplantation raise a
lot of issues regarding the use of MSCs as a “pharmaceutical
product” or “stem cells drug.” The first issue is obtaining “clinical
grade” MSCs of superior reproducible quality and reasonable cost
(Golchin et al., 2020). Besides, factors such as timing of MSCs
administration related to the severity of the case, especially with
a disease such as COVID-19 pneumonia, frequency of dosing,
number of cells and route of administration, either through
injection or inhalation are all open questions that require further
investigations. Especially that efficiency of MSCs therapeutics
could be largely dependent on the route of delivery, as well
as the transplantation regimen (Giri and Galipeau, 2020). We
tackled these issues about WJ-MSCs potentials/challenges to treat
diabetes in a review (Kamal and Kassem, 2020). We think that
MSCs application in viral infections generally, and respiratorytract viral infections particularly is a field that warrant further
investigation, pre-clinical and clinical trials to sharpen this
readily available weapon in preparation to upcoming pandemics
like the one we are suffering right now.
It’s noteworthy here that given the non-invasive property
of isolating MSCs from umbilical-cord, MSCs derived from
UC-tissue (WJ-MSCs) have been particularly suggested as a
potential option in these dangerous times for treating criticallyill COVID-19 patients under compassionate use protocols
(Atluri et al., 2020). Importantly, we have to differentiate
between the UC-tissue and the UC-blood (UCB). Each of these
compartments provides different types of stem cells; MSCs are
predominantly abundant in the UC-tissue/WJ, rather than UCB
(Shetty et al., 2010).
Recently, few published reports shared some results from
pilot studies which investigated the safety/efficacy of MSCs for
COVID-19. Of these, a case report revealed the efficacy of WJMSCs infusion in a critically-ill COVID-19 patient. In that
study, the authors reported that pulmonary functions showed
significant improvement in 2 days, and the patient was discharged
in 7 days after receiving cell-therapy (Zhang Y. et al., 2020).
In another study, a total of ten patients were enrolled; seven
patients (1 critically-ill, 4 with severe symptoms, and 2 with mild
symptoms) received MSCs-transplantation, while three patients
(with severe symptoms) served as the control group and received
placebo (Leng et al., 2020). After receiving MSCs intravenously,
nearly all symptoms showed significant improvement within
2–4 days post-infusion, even the critically-ill elderly patient
who received MSCs, showed an overall improvement and
recovered. Moreover, pro-inflammatory cytokines showed
dramatic reduction, this was associated with improvements
in leukocytes-count, as well as increased levels of IL-10 and
VEGF which promoted lung-repair. Furthermore, remarkable
reduction in pneumonia infiltration was observed in chest
computed-tomography scans, and patients did not suffer any
side effects. On the other hand, regarding the placebo group, 1
patient died, and the other 2 remained suffering severe symptoms
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DISCUSSION
Knowing that severity of COVID-19 is mostly dependent on
the patients’ own immune-response, since over-activation of
the immune-system can cause a “cytokine storm” which in
turn can cause ARDS, multi-organ damage, and ultimately
may lead to death. Thus, harnessing the immunomodulatory
properties of MSCs to ameliorate that cytokine-storm can indeed
provide a golden key for treating severe cases of COVID19. In fact, MSCs-transplantation can improve the overall
outcome of COVID-19 via multiple strategies; (a)through their
immunomodulatory effects, (b)via promoting tissue-repair and
regeneration, (c)through their antifibrotic, as well as angiogenic
and anti-microbial effects as summarized in Figure 1. All
these mechanisms will interplay and intervene together to
enhance lung-repair and protect various organs from any damage
resulting from exaggerated immune-response.
Nevertheless, it’s important to keep in mind the concerns
regarding suggested pro-coagulant effect of MSCs and/or their
derived EVs (Silachev et al., 2019), especially for COVID19 patients. Thus, for vulnerable patients, it’s important
to keep an eye on patient coagulopathy and take proper
thromboprophylactic measures while the clinical application of
MSCs (Moll et al., 2020). Furthermore, in this regard, tissue factor
(TF/CD142/coagulation factor III) has been highlighted as a
major determinant of cell product hemocompatibility (Moll et al.,
2019). TF/CD142 is a glycoprotein which triggers the coagulation
cascade via inducing thrombin formation from pro-thrombin
(Witkowski et al., 2016). Thus, MSCs which are going to be
used for COVID-19 should express only low levels of TF/CD142,
since the molecule by itself may initiate the clotting process, and
also because MSCs from different sources have been reported
to express varying degrees of TF/CD142 (Moll et al., 2019). It’s
also important to remember the statement by the international
society of extracellular-vesicles (ISEV) and international society
for cell and gene therapy (ISCT) regarding the potential of MSCsderived EVs as a treatment for COVID-19, and announcing that
they do not currently endorse their use in COVID-19, without
the generation of appropriate manufacturing and quality-control
provisions, as well as pre-clinical safety and efficacy data, and
proper regulatory oversight (Börger et al., 2020).
Conclusively, the published findings until now regarding
therapeutic potential of MSCs for inflammatory-conditions
generally, and for COVID-19 specifically are indeed encouraging.
Nevertheless, several un-answered open-questions and critical
issues should be carefully considered as summarized in Figure 2,
and some of these issues remain as black boxes. These include
whether pre-conditioning of MSCs will impact their beneficial
therapeutic effects for COVID-19 or not. Accordingly, further
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research is warranted to elucidate how the process of MSCsisolation and culture/expansion can be optimized in order to
produce MSCs with the best therapeutic properties for COVID19, not only in large amounts, but also in a reproducible
manner. Such optimized approaches will help us to achieve
tailored therapies for any condition generally, and for COVID19 particularly, in a form of “personalized medicine” ultimately
improving the cost-benefit returns (Pittenger et al., 2019).
Finally, MSCs derived from various sources were reported to
have different properties in varying contexts. Thus, MSCs derived
from which of these sources could provide the best therapeutic
outcome for COVID-19 patients remains largely unknown.

Future well-designed large-scale randomized-controlled trials
comparing the therapeutic effects of MSCs derived from different
sources will provide important insights in this regard. Similar
studies are also warranted to compare the therapeutic benefit of a
certain MSCs type, and its derived EVs.
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